不孕与分娩后新发系统性自身免疫性风湿病之间的关联:一项基于人群的队列研究
该研究利用加拿大安大略省2012至2021年关联行政数据,纳入465 078名18至50岁无已知既存系统性自身免疫性风湿病(SARD)女性的568 053例单胎分娩,评估不孕(伴或不伴生育治疗)与产后新发SARD的关联。中位随访6.5年,不孕未治疗组SARD发生率高于无不孕组,控制不良妊娠结局后风险仍升高(控制直接效应HR 1.25,95%CI 1.12-1.40);非侵入性和侵入性生育治疗均与SARD无显著关联。
要点
- 不孕未接受生育治疗者产后9年内SARD发生率高于无不孕者。
- 控制先兆子痫、自发性早产和死产等不良妊娠结局后,不孕未治疗与SARD风险升高仍相关(控制直接效应HR 1.25,95%CI 1.12-1.40)。
- 非侵入性(总效应HR 1.06,95%CI 0.79-1.42)和侵入性(总效应HR 0.97,95%CI 0.69-1.36)生育治疗均与SARD无显著关联。
核心结论
- 不孕但未接受生育治疗的女性分娩后SARD发生率高于无不孕女性,即使控制其较高的先兆子痫、自发性早产和死产发生率后仍如此。
- 无生育治疗的不孕可能是分娩女性SARD的重要风险标志。
- 提高医疗提供者对不孕女性可能存在的SARD症状及相关妇科问题的认识,可能有助于在育龄期更早发现和治疗SARD。
研究设计与样本
- 基于人群的队列研究,使用加拿大安大略省2012至2021年关联行政数据,纳入465 078名18至50岁无已知既存SARD女性的568 053例单胎分娩。
- 暴露分为:无不孕且自然受孕(参照组,占队列88.0%)、不孕未接受生育治疗(9.2%)、不孕接受非侵入性生育治疗(排卵诱导或宫内授精,1.4%)、不孕接受侵入性生育治疗(IVF或ICSI,1.4%)。
- SARD通过基于诊断代码的验证算法识别(两次医生就诊、一次风湿科就诊或一次住院),从指数分娩日期起测量,随访截至2021年3月31日。
- 采用边际结构Cox比例风险模型生成风险比(HR)和95%CI,表示调整社会人口学特征、合并症和吸烟后的总效应,以及额外控制不良妊娠结局后的控制直接效应。
主要发现
- 中位(IQR)随访时间为6.5(4-9)年。
- SARD发生率:无不孕女性为9.3/10 000人年,不孕未治疗者为12.5/10 000人年,非侵入性生育治疗后为10.9/10 000人年,侵入性生育治疗后为10.9/10 000人年。
- 不孕未治疗与SARD风险升高相关,控制不良妊娠结局后控制直接效应HR 1.25(95%CI 1.12-1.40)。
- 非侵入性生育治疗与SARD无显著关联(总效应HR 1.06,95%CI 0.79-1.42)。
- 侵入性生育治疗与SARD无显著关联(总效应HR 0.97,95%CI 0.69-1.36)。
临床怎么用
- 作者认为,无生育治疗的不孕可能是分娩女性SARD的重要风险标志。
- 作者认为,提高医疗提供者对不孕女性可能存在的SARD症状及相关妇科问题的认识,可能有助于在育龄期更早发现和治疗SARD。
局限性
- 暴露和结局误分类可能存在,因研究使用卫生行政数据中的已发表算法,其敏感性和特异性未知或不完美。
- 个体水平的社会和生活方式因素及不孕的根本原因数据不可获得,因此未纳入分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the association between infertility with or without fertility treatment and incident onset of systemic autoimmune rheumatic disease (SARD) among women who give birth? SUMMARY ANSWER: Women who experienced infertility but did not use fertility treatment had a higher incidence of SARD up to 9 years after delivery than those who did not experience infertility, even after accounting for their higher rates of preeclampsia, spontaneous preterm birth, and stillbirth. WHAT IS KNOWN ALREADY: Infertility is increasingly common and is an under-appreciated risk marker for chronic diseases in women. Despite several studies documenting abnormal immune activity in women with infertility, little is known about the association between infertility and incidence of autoimmune diseases such as SARD which disproportionately develops in reproductive-aged women. STUDY DESIGN, SIZE, DURATION: This population-based cohort study using linked administrative data for all of ON, Canada, 2012-2021 and included 568 053 singleton births among 465 078 women aged 18-50 years without known pre-existing SARD. PARTICIPANTS/MATERIALS, SETTING, METHODS: The exposures were: (i) no infertility with unassisted conception (referent [88.0% of the cohort]); (ii) infertility without fertility treatment (9.2%); (iii) infertility with non-invasive fertility treatment (ovulation induction or intrauterine insemination [1.4%]); and (iv) infertility with invasive fertility treatment (IVF or ICSI [1.4%]). SARD was identified by a validated algorithm based on diagnostic codes at two physician visits, one rheumatologist visit, or one hospitalization and measured from the index delivery date, with censoring at death, loss of health insurance, or study end of 31 March 2021. Marginal structural Cox proportional hazards models generated hazard ratios (HR) and 95% CIs representing total effects adjusted for sociodemographic characteristics, comorbidities, and smoking, and controlled direct effects additionally accounting for adverse pregnancy outcomes. MAIN RESULTS AND THE ROLE OF CHANCE: The median (IQR) duration of follow-up was 6.5 (4-9) years. The incidence rate of SARD was 9.3 per 10 000 person-years in women without infertility, 12.5 per 10 000 person-years in those with infertility and no fertility treatment, 10.9 per 10 000 person-years following non-invasive fertility treatment, and 10.9 per 10 000 person-years after invasive fertility treatment. Infertility without treatment was associated with an elevated risk of SARD, even after accounting for adverse pregnancy outcomes (controlled direct effect HR 1.25, 95% CI 1.12-1.40). Neither non-invasive (total effect HR 1.06, 95% CI 0.79-1.42) nor invasive (total effect HR 0.97, 95% CI 0.69-1.36) fertility treatments were associated with SARD. LIMITATIONS, REASONS FOR CAUTION: Exposure and outcome misclassification is possible as this study used published algorithms in health administrative data with unknown or imperfect sensitivity and specificity. Data on individual-level social and lifestyle factors and underlying causes of infertility were not available and thus were not included in the analysis. WIDER IMPLICATIONS OF THE FINDINGS: Infertility in the absence of fertility treatment may be an important risk marker for SARD in women who give birth. Greater health provider awareness of SARD symptoms and related gynaecological issues that may be present in women with infertility could facilitate earlier detection and treatment of SARD during the reproductive years. STUDY FUNDING/COMPETING INTERESTS(S): This research was funded by the Canadian Institutes of Health Research through a Banting Postdoctoral Fellowship to N.V.S. and Canada Research Chair to H.K.B. (2019-00158) and was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and the Ministry of Long-Term Care. The analyses, conclusions, opinions, and statements expressed herein are solely those of the authors and do not reflect those of the funding organizations; no endorsement is intended or should be inferred. The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication. M.Y.C. has consulted for Celltrion, Werfen, Organon, MitogenDx, AstraZeneca, Mallinckrodt Canada Inc, and Glaxo Smith Kline. All other authors have no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Scime NV, Velez MP, Choi MY, et al. Association between infertility and incident onset of systemic autoimmune rheumatic disease after childbirth: a population-based cohort study. Hum Reprod. 2025. PMID: 39656875. doi:10.1093/humrep/deae253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。